down arrow

Centuple Global

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE396H01019
  • NSEID:
  • BSEID: 531099
  • View on BSE
INR
32.99
0.99 (3.09%)
BSENSE

Sep 25, 10:44 AM

BSE+NSE Vol: 1.0 k

Access older stock analysis version
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Unjha Formul.
Colinz Labs
Centuple Global
Ishita Drugs
Desh Rakshak
Zenith Health
Venmax Drugs
Welcure Drugs
Shree Ganesh Bio
Saroja Pharma In
Mono Pharmacare

Why is Centuple Global Ltd ?

1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.45
  • The company has been able to generate a Return on Capital Employed (avg) of 8.26% signifying low profitability per unit of total capital (equity and debt)
2
Below par performance in long term as well as near term
  • Along with generating -28.36% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Centuple Global for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Centuple Global
-28.36%
-0.43
65.30%
Sensex
-9.28%
-0.68
13.60%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
254.85%
EBIT Growth (5y)
24.49%
EBIT to Interest (avg)
0.45
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
3.22
Sales to Capital Employed (avg)
7.07
Tax Ratio
33.62%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
11.15%
ROCE (avg)
11.21%
ROE (avg)
15.67%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
12
Industry P/E
38
Price to Book Value
8.47
EV to EBIT
12.07
EV to EBITDA
12.07
EV to Capital Employed
2.77
EV to Sales
0.04
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
22.15%
ROE (Latest)
72.63%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company
NET SALES(9M)

At Rs 453.50 cr has Grown at 3,660.36%

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...

Here's what is working for Centuple Global

Net Sales - Latest six months
At Rs 279.41 cr has Grown at 2,236.20%
Year on Year (YoY)
MOJO Watch
Sales trend is very positive

Net Sales (Rs Cr)

Footer loading